Dandekar Atul sold $198K of MAZE
Dandekar Atul (CSBO) sold 7,500 shares of Maze Therapeutics, Inc. (MAZE) at $26.34 ($0.20M total) on 2026-05-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This is a disclosed open-market sale by an officer under a pre-arranged 10b5-1 plan, which generally has limited incremental impact on valuation expectations.
Market read
Traders may note the insider sale, but the 10b5-1 structure suggests it is not a fresh discretionary bearish signal.
What to watch
The article provides no context on total insider holdings, other concurrent transactions, or whether the sale was tax-related, limiting signal strength.
Background
The article is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
Maze Therapeutics disclosed an officer open-market sale of 7,500 shares at $26.3405 on a 10b5-1 plan, filed June 2.
Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted.
The transaction is explicitly labeled as a pre-arranged 10b5-1 plan and is an open-market sale, which typically reduces interpretive value versus discretionary selling.
Market effects
Minimal, as this is company-specific insider trading with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Insider sales can still reflect private information, but the 10b5-1 designation makes that interpretation less reliable.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderDandekar Atul
Officer who sold 7,500 shares under a 10b5-1 plan.
